Skip to main content

Table 1 Data on discordance of ER, PgR and HER2 status between primary and metastatic breast cancer

From: Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives

Reference ER discordance (%) PgR discordance (%) HER2 discordance (%)
Lindstrom et al. [7] 32.4 40.7 14.5
Niikura et al. [8] NR NR 43
Curigliano et al. [9] 15 49 14
Gong et al. [10] 7 NR NR
Amir et al. [2] 12.6 31.2 5.5
Bogina et al. [11] 6 21 1
Wilking et al. [12] NR NR 10
Aitken et al. [13] 28 23 9
Amir et al. [4] 16 40.4 9.6
Idirisinghe et al. [14] 16 38 5
Simmons et al. [15] 40 40 8
Liedtke et al. [16] 18 40 14
Lower et al. [17] NR NR 33
Broom et al. [18] 17.7 37.3 5.5
Santinelli et al. [19] NR NR 18.9
Tapia et al. [20] NR NR 8
Lower et al. [21] 30 39 NR
Carlsson et al. [22] NR NR 0
Edgerton et al. [23] NR NR 15
Gancberg et al. [24] NR NR 9
Simon et al. [25] NR NR 3
Mobbs et al. [26] 14 28 NR
Guarneri et al. [27] 22 36 16
Hoefnagel et al. [28] 10.3 30 5.2
Thompson et al. [5] 10.2 24.8 2.9
Brogi et al. [29] 16.2 20.6 5
Chang et al. [30] 25 NR 12.5
  1. ER, estrogen receptor; HER, human epidermal growth factor receptor; NR, not reported; PgR, progesterone receptor.